PPR

Prairie Provident Resources Announces Fourth Quarter and Year-End 2023 Financial and Operating Results

Retrieved on: 
Tuesday, April 2, 2024
Evi, Natural gas, Sale, MD, Bank statement, TSX, PPR, CAD

CALGARY, Alberta, April 02, 2024 (GLOBE NEWSWIRE) -- Prairie Provident Resources Inc. ("Prairie Provident" or the "Company") (TSX:PPR) announces its operating and financial results for the fourth quarter and year ended 2023.

Key Points: 
  • CALGARY, Alberta, April 02, 2024 (GLOBE NEWSWIRE) -- Prairie Provident Resources Inc. ("Prairie Provident" or the "Company") (TSX:PPR) announces its operating and financial results for the fourth quarter and year ended 2023.
  • Production averaged 3,413 boe/d (64% liquids) for the fourth quarter of 2023, a 9% decrease from the same period in 2022.
  • Fourth quarter 2023 operating netback1 before the impact of derivatives was $3.2 million ($10.03/boe), and $2.9 million ($9.07/boe) after realized losses on derivatives, a $3.4 million decrease and $0.6 million increase, respectively, from the fourth quarter of 2022.
  • Net capital expenditures1 for the fourth quarter of 2023 of $0.7 million were primarily for the retention of mineral and surface leases.

Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients

Retrieved on: 
Tuesday, March 26, 2024
EEG, Central nervous system, Epilepsy, Patient, CNS, PPR, Pharmaceutical industry

BOSTON, March 26, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided an update on its Phase 2a proof of concept study evaluating PRAX-628 in epilepsy patients with PPR. PPR studies measure electroencephalogram (EEG) signatures after intermittent photic stimulation and are used as an indicator of anti-seizure efficacy.

Key Points: 
  • PPR studies measure electroencephalogram (EEG) signatures after intermittent photic stimulation and are used as an indicator of anti-seizure efficacy.
  • “The strength and consistency of response across both study arms, combined with a continued positive tolerability and safety profile, build on our earlier conviction that PRAX-628 has the potential to be the first precision sodium channel modulator for focal epilepsy patients.
  • With such a clear response, we have advanced our planning of the focal epilepsy efficacy study for PRAX-628, expected to begin in the second half of 2024.
  • We extend our thanks to the patients who participated in this PPR study,” said Marcio Souza, president and chief executive officer of Praxis.

Cable Blowing Equipment Market size is set to grow by USD 42.34 mn from 2024-2028, growing fiber optic deployment boost the market- Technavio

Retrieved on: 
Tuesday, March 19, 2024
PVC, CAPEX, TIC, Pneumatics, Growth, Communication, Electricity, Compressed air, OTT, Data, FTTC, Fiber to the x, Bharat Broadband Network, FTTP, STI, FTTB, CBS, FTTH, Telecommunications, PPR, Ministry, Microducts, Retail

View Sample Report

Key Points: 
  • View Sample Report
    Cable Blowing Equipment Market  is fragmented ; the companies are competing with competitors and are trying to get greater market share.
  • Cable Blowing Equipment Market report includes information on the product launches, sustainability, and prospects of leading vendors including Adishwar Tele Networks Pvt.
  • This market encompasses various types of cable blowing machines, including PVC, PPR, and composite cable blowing equipment.
  • The market for cable blowing equipment is driven by the growing demand for reliable and efficient communication and power infrastructure.

AleutianStar JV Awarded Contract for Data Analytics Support with Department of State

Retrieved on: 
Tuesday, March 12, 2024
Propaganda, Democracy, Partnership, Nation, Strategic planning, Artificial intelligence, DOS, National security, Machine learning, PPR, Public diplomacy, Marketing, State, Public affairs

WASHINGTON, March 12, 2024 /PRNewswire/ -- AleutianStar JV, LLC (AleutianStar), has received a multi-year contract award by the Department of State's (DOS) Office of the Under Secretary for Public Diplomacy and Public Affairs (R), Office of Policy, Planning, and Resources (PPR) to provide comprehensive support for the DOS's public diplomacy efforts through advanced data analytics.

Key Points: 
  • WASHINGTON, March 12, 2024 /PRNewswire/ -- AleutianStar JV, LLC (AleutianStar), has received a multi-year contract award by the Department of State's (DOS) Office of the Under Secretary for Public Diplomacy and Public Affairs (R), Office of Policy, Planning, and Resources (PPR) to provide comprehensive support for the DOS's public diplomacy efforts through advanced data analytics.
  • "This contract underscores our commitment to leveraging innovative technologies to drive positive outcomes for our clients.
  • By harnessing the power of data analytics, we aim to empower the DOS in its mission to engage effectively with global audiences."
  • This strategic partnership brings together two industry leaders with complementary expertise in data analytics and technology solutions.

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Tuesday, March 5, 2024
Central nervous system, Quarter, EMA, Focal seizure, Research, New Drug Application, UCB, FDA, Partnership, Food, Part, Quantitative electroencephalography, SCN8A, Tremor, SCN2A, Safety, PPR, European Medicines Agency, CNS, EEG, Pharmacokinetics, Part 1, Patient, Essential tremor, Medicine, Epilepsy, DEE, Trial of the century, NDA, Ageing, Central nervous system disease, Seizure, Pharmaceutical industry

Fourth Quarter and Full Year 2023 Financial Results:

Key Points: 
  • Fourth Quarter and Full Year 2023 Financial Results:
    As of December 31, 2023, Praxis had $81.3 million in cash and cash equivalents, compared to $100.5 million in cash, cash equivalents and marketable securities as of December 31, 2022.
  • Research and development expenses were $18.4 million for the fourth quarter of 2023, compared to $28.3 million for the fourth quarter of 2022.
  • General and administrative expenses were $9.9 million for the fourth quarter of 2023, compared to $13.1 million for the fourth quarter of 2022.
  • Praxis incurred a net loss of $26.9 million for the fourth quarter of 2023, including $5.7 million of stock-based compensation expense, compared to $41.2 million for the fourth quarter of 2022, including $6.4 million of stock-based compensation expense.

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, February 26, 2024
HER2, PFS, AAAAI, KIT, Research, Completeness, TSS, ASCO, ASH, WT, Cash, Part, Safety, PEAK, AACR, Cogent, Conference, GIST, Society, PPR, Patient, The, PIPE, FGFR2, Clinical trial, Poster, G&A, Sunitinib, Initiate, IND, Brain, TKI, APEX, Cancer, American Academy, Pharmaceutical industry

WALTHAM, Mass. and BOULDER, Colo., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and reported financial results for the fourth quarter and full year of 2023.

Key Points: 
  • and BOULDER, Colo., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and reported financial results for the fourth quarter and full year of 2023.
  • SUMMIT is a registration-directed, randomized, double-blind, placebo-controlled, global, multicenter, clinical trial of bezuclastinib in patients with nonadvanced systemic mastocytosis (NonAdvSM).
  • Cash and Cash Equivalents: As of December 31, 2023, Cogent had cash, cash equivalents and marketable securities of $273.2 million.
  • During the quarter Cogent also completed and paid for bulk manufacturing campaigns of bezuclastinib to continue supporting the company’s clinical trials.

Prairie Provident Announces Year-End 2023 Reserves

Retrieved on: 
Thursday, February 22, 2024
TP, PDP, RLI, Oil, Operational definition, National instrument, P+P, PPR

(1) PPR calculates Reserve Life Index (RLI) based on the estimated reserves amount as at December 31, 2023 for the relevant reserves category, as evaluated by Sproule, divided by actual 2023 annual production.

Key Points: 
  • (1) PPR calculates Reserve Life Index (RLI) based on the estimated reserves amount as at December 31, 2023 for the relevant reserves category, as evaluated by Sproule, divided by actual 2023 annual production.
  • See “Cautionary Statements – Disclosure of Oil and Gas Reserves Data and Operational Information” and “Cautionary Statements – Reserve Life Index”.
  • This resulted in positive reserve additions of 0.3 MMboe, 0.1 MMboe, and 0.1 MMboe for PDP, TP, and P+P reserves, respectively.
  • The following table is a summary of the Company's estimated reserves as at December 31, 2023, as evaluated in the Sproule Report.

Premiere Plus Realty Joins United Real Estate's National Network

Retrieved on: 
Friday, March 8, 2024
Collection, Golf, Growth, Family, Knowledge, PPR, Real estate

DALLAS, March 8, 2024 /PRNewswire-PRWeb/ -- United Real Estate (United) announced today that Premiere Plus Realty (PPR), the Naples-based, No. 2 market share leader in Southwest Florida, has joined its family of companies. Premiere Plus Realty and its 1,500 agents retain their company name, staff and leadership. With this affiliation, PPR greatly expands its tools and service offerings for agents and their clients.

Key Points: 
  • Southwest Florida brokerage expands tools, programs and brokerage services for its affiliated real estate professionals and customers
    DALLAS, March 8, 2024 /PRNewswire-PRWeb/ -- United Real Estate (United) announced today that Premiere Plus Realty (PPR), the Naples-based, No.
  • "Their resources, including Learning Academy, Financial Wellness, United Referral Network and United Real Estate Group Healthcare, are unique in our market and further differentiate us from competing brokerages.
  • United has increased our value," commented Premiere Plus Realty President Jillian Young.
  • "Over 20 years ago, Premiere Plus Realty was founded with the sole purpose of putting agents and clients above themselves.

Ekinops' 2023 annual results: EBITDA margin of 14.4%

Retrieved on: 
Tuesday, March 5, 2024
Software, ERP, Acquisition, Corporate social responsibility, Investment, Growth, WDM, CSR, Access, Travel, Earnings, Tax, Policy, Optics, FY, PPR, Service, Depreciation, Clothing

Revenue generated by Software & Services rose by +12% in 2023, driven by sales of network virtualization solutions, SD-WAN solutions and services.

Key Points: 
  • Revenue generated by Software & Services rose by +12% in 2023, driven by sales of network virtualization solutions, SD-WAN solutions and services.
  • In this complex economic environment, gross margin amounted to 67.3 m€ in 2023, same as the previous year (67.6 m€).
  • EBITDA1 margin was 14.4% in 2023, compared with a record-high level of 17.7% in the previous year.
  • Operating cash flow of 13.5 m€ in 2023, 7.8 m€ in total cash generation
    FY 2023 illustrates Ekinops' ability to generate cash through its business.

PPR Capital Management Promotes Taylor Nelson to Director of Non-Performing Loan Investments

Retrieved on: 
Wednesday, January 31, 2024
PPR, Criminology, Pennsylvania State University, NPL, Statistics, Investment management, Joint venture, Data analysis, Investment, Information, Non-performing loan, Investment strategy, Forecasting

BERWYN, Pa., Jan. 31, 2024 /PRNewswire/ -- PPR Capital Management, a private equity real estate investment firm, has announced the promotion of Taylor Nelson to Director of Non-Performing Loan Investments. In this role, Nelson will lead PPR's Non-Performing Loan (NPL) business vertical and will be responsible for acquisitions, surveillance and performance of the firm's NPL business line and Joint Venture partnerships. Nelson previously served as the firm's Senior Acquisition and Portfolio Analyst since 2020.

Key Points: 
  • Having Purchased Over $440 Million In the Past Two Years, Nelson Leads the Firm's Expansion of its NPL Business Model
    BERWYN, Pa., Jan. 31, 2024 /PRNewswire/ -- PPR Capital Management , a private equity real estate investment firm, has announced the promotion of Taylor Nelson to Director of Non-Performing Loan Investments.
  • In this role, Nelson will lead PPR's Non-Performing Loan (NPL) business vertical and will be responsible for acquisitions, surveillance and performance of the firm's NPL business line and Joint Venture partnerships.
  • "Taylor has been a champion of PPR's continued expansion into the NPL vertical and a major contributor to the firm's success in this area," said Steve Meyer, CEO of PPR Capital Management.
  • "As Director of NPL Investments I'm excited about the opportunity to maximize PPR's NPL portfolio," said Nelson.